Unlock China’s Healthcare Opportunities

Access deals, gain insights and connect with innovators.

About VCBeat

IN FOCUS

Moutai Invests in a Biotech Company

Recently, Comvikin has completed its Series B financing. The investors in this round include Puhua Capital, Delian Capital, CDH Investments, Orient Renaissance Capital, and the renowned Moutai.

FINANCE

VIEW ALL

September 11, 2025

GenFleet Therapeutics to list on the Hong Kong Stock Exchange on the 19th, with anchor investors subscribing for USD 100 million

On September 11, 2025, GenFleet Therapeutics released its global offering document, with CITIC Securities acting as the sole sponsor.

INNOVATIONS

VIEW ALL

September 11, 2025

World’s first anti-scar drug: Mabwell Biosciences’ IL-11 antibody targets trillion-yuan fibrosis and anti-aging markets

Mabwell announced that its innovative IL-11 monoclonal antibody drug, 9MW3811, has been accepted by the NMPA for a Phase II clinical trial application targeting pathological scars. This marks the world’s first IL-11 targeted therapy to enter the clinical stage for the treatment of pathological scars.

MNC CHINA LENS

VIEW ALL

September 08, 2025

Japanese pharmaceutical company's RMB 1.1 billion investment project kicks off, accelerating local innovation in ADC drug R&D

Daiichi Sankyo, a Japanese pharmaceutical company, has announced the official commencement of construction on a new antibody-drug conjugate (ADC) manufacturing facility in Shanghai’s Zhangjiang area, with a total investment of approximately RMB 1.1 billion. As one of China’s first pilot projects for cross-border, segmented manufacturing of biologics, this initiative will be rooted in the Chinese market to establish a localized ADC production base, significantly enhancing the domestic supply capacity of ADC innovative drugs.

ASPECTS

VIEW ALL

September 10, 2025

Maxwell achieves high-precision, standardized intelligent simulation prosthesis customization

Maxwell started its business with breast prostheses. Leveraging technologies such as digital design, 3D printing, and automated coloring processes, it has built an efficient, replicable, and highly personalized production system and is expanding into customized prosthetic ears, noses, and even robotic simulation skin.

RESEARCH

VIEW ALL

September 04, 2025

Kaiyuan Securities: Tracking Global Cutting-Edge Progress in the Weight Loss Sector (II) — Orforglipron Leads the Global Small-Molecule GLP-1RA Race as Domestic Pipeline Value Gradually Emerges

Small-molecule GLP-1RAs offer numerous advantages, including low cost, unrestricted usage scenarios, and no need for cold-chain transportation, giving them broad development prospects. In the small-molecule GLP-1RA race, Eli Lilly and Company’s Orforglipron has completed global Phase III trials for both diabetes and obesity, maintaining a leading position worldwide. AstraZeneca’s AZD5004, Roche’s CT-996, Lilly’s Naperiglipron, and Terns’ TERN-601 have all entered Phase II, with overall progress advancing rapidly. Among domestic companies, Hengrui Pharma, Huadong Medicine, and Ascletis Pharma, among others, are actively building small-molecule GLP-1RA pipelines. In recent years, this track has witnessed multiple high-profile BD transactions, and its growth momentum continues to strengthen.

Download Preview

September 03, 2025

2025 Chemical Pharmaceutical Enterprises Organizational Efficiency Report

As of August 8, 2025, Shunwei Consulting collected organizational effectiveness data for 158 publicly listed chemical pharmaceutical companies through databases such as iFind. Among these, 111 are finished-dosage chemical drug companies and 47 are active pharmaceutical ingredient (API) companies.


Considering both company influence and revenue, companies with negative net profit (e.g., BeOne Medicines, Nenter) were excluded. From the remaining A-share listed companies, the top 10 chemical pharmaceutical companies by revenue were selected as benchmark enterprises for organizational effectiveness analysis.


To provide a comprehensive view of the industry, the selected companies cover various segments: innovative drug R&D (e.g., Hengrui Medicine, Humanwell Healthcare), high-end generics and internationalized formulations (e.g., Fosun Pharma, Kelun Pharma), and specialty APIs and complex formulations (e.g., Apeloa Pharmaceuticals, Livzon Group).

Download Preview

September 02, 2025

Global Healthcare Investment and Financing Monthly Report for August 2025

In August 2025, a total of 150 financing events occurred globally in the healthcare sector (excluding IPOs, private placements, etc.), with a disclosed total financing amount of approximately USD 3.647 billion (around RMB 26.032 billion), according to incomplete statistics from VCBeat. Among these, the domestic market recorded 81 financing events with a total disclosed amount of approximately USD 942 million, while the overseas market recorded 69 financing events totaling approximately USD 2.705 billion.


Compared with July 2025 in terms of transaction amounts, number of financing events, and focus on emerging fields, the number of global healthcare financing events in August 2025 increased by approximately 11.11% month-on-month, while the total financing amount fell sharply by about 47.27%.


Regarding large financing events, 10 deals exceeded USD 100 million this month, with a cumulative financing amount of USD 1.511 billion. Among these, 9 occurred overseas and 1 domestically. The 10 companies are:


Kriya Therapeutics – gene therapy drug developer

EliseAI – healthcare system developer

Strand Therapeutics – biopharmaceutical company

Minghui Pharma – innovative drug developer

Apreo Health – device developer for emphysema treatment

Wugen – cell therapy developer

SetPoint Medical – developer of novel bioelectronic medical therapies

Restor3d – 3D-printed implant supplier

Eight Sleep – sleep health service provider

Nudge – developer of ultrasonic phased-array equipment

Download Preview

AWARDS

VIEW ALL

July 05, 2025

Top innovative healthcare assets in China ranked for June 2025
This ranking highlights the latest publicly disclosed fundraising events and business development deals, offering a clear view of the evolving landscape of China's healthcare market.

May 10, 2025

Future Healthcare Rankings in China Top Ten Healthcare Industry Service Chain Companies in 2025
This ranking targets non-listed enterprises in the healthcare sector. Based on the VB100 Value Assessment Model, the selection process involves enterprise self-nomination, review by the VB100 Evaluation Committee, cross-review by supporting institutions, and final approval by an expert committee. From the category of healthcare industry chain services, the top 100 innovative companies by valuation are selected (this article excerpts the top 10 ranked enterprises). Beyond valuation, supplementary research will be conducted on the growth and annual performance of candidate enterprises across four primary indicators—human resources, knowledge resources, key partnership resources, and market performance—comprising a total of 17 secondary metrics.

May 10, 2025

Future Healthcare Rankings in China Top Ten Innovative Medical and Health Services Companies in 2025
This ranking targets non-listed enterprises in the healthcare sector. Based on the VB100 Value Assessment Model, the selection process involves enterprise self-nomination, review by the VB100 Evaluation Committee, cross-review by supporting institutions, and final approval by an expert committee. From the category of medical and health innovation services, the top 100 innovative companies by valuation are selected (this article excerpts the top 10 ranked enterprises). Beyond valuation, supplementary research will be conducted on the growth and annual performance of candidate enterprises across four primary indicators—human resources, knowledge resources, key partnership resources, and market performance—comprising a total of 17 secondary metrics.

May 10, 2025

Future Healthcare Rankings in China Top Ten Pharmaceuticals and Biologics Companies in 2025
This ranking targets non-listed enterprises in the healthcare sector. Based on the VB100 Value Assessment Model, the selection process involves enterprise self-nomination, review by the VB100 Evaluation Committee, cross-review by supporting institutions, and final approval by an expert committee. From the categories of innovative pharmaceuticals and biological products, the top 100 innovative companies by valuation are selected (this article excerpts the top 10 ranked enterprises). Beyond valuation, supplementary research will be conducted on the growth and annual performance of candidate enterprises across four primary indicators—human resources, knowledge resources, key partnership resources, and market performance—comprising a total of 17 secondary metrics.

EVENTS

VIEW ALL

18

Aug

"@LOGOS" Multi-omics Salon

Hall A1005, ATLATL Innovation and Research Center, No. 1077 Zhangheng Road, Pudong New Area, Shanghai

August 18, 2025

Learn More

Subscribe to our Newsletter Now

Exclusive updates and insights on healthcare innovation and Chinese market straight to your inbox